Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Amgen (AMGN) PT Raised to $352 at Leerink Partners
November 27, 2024 6:19 AM UTCLeerink Partners analyst David Risinger raised the price target on Amgen (NASDAQ: AMGN) to $352.00 (from $305.00) while maintaining a Market Perform rating.
The analyst comments "Bottom Line: We are lowering our PT from $352 (18x 2025E EPS of $19.55) to $305 (15x 2025E EPS of $20.33) and maintaining our Market Perform rating. We lowered our 5- yr (25-30) CAGR EPS from 8% to 4%, largely driven by higher investment spending assumptions. MariTides Ph2 results... More
Increasing unusual call option volume: KULR RGTI MSTZ NNE QBTS PL DKS SJM VUZI ARQT KODK SIGA SMTC WSM RDW HST AMGN BLBD
November 26, 2024 10:26 AM UTCIncreasing unusual call option volume: KULR RGTI MSTZ NNE QBTS PL DKS SJM VUZI ARQT KODK SIGA SMTC WSM RDW HST AMGN BLBD
... MoreAmgen falls after obesity study results
November 26, 2024 8:07 AM UTCInvesting.com --Â Shares of Amgen (NASDAQ: NASDAQ: AMGN) dropped 7.4% in premarket trading Tuesday following the release of Phase 2 trial results for its obesity drug candidate, MariTide (formerly AMG 133).
While the study demonstrated notable weight-loss potential, investor expectations for the drug's efficacy may have been higher, contributing to the stock's decline.
... MoreMorgan Stanley on Amgen (AMGN): 'Initial thoughts on Maritide Ph2 diabesity data'
November 26, 2024 7:58 AM UTCMorgan Stanley analyst Terance Flynn reiterated an Equalweight rating and $22.00 price target on Amgen (NASDAQ: AMGN)
The analyst comments "AMGN reported top-line data from a Ph2 trial of Maritide for diabesity (HERE). Based on the press release the data appear most similar to Scenario 3 which we previewed see our note HERE: We would expect AMGN to trade up +5-10%; we would expect LLY to trade down... More
Amgen (AMGN) Falls 8% Following Obesity Data, Rivals Lilly (LLY), Novo Nordisk (NVO) Gain 4%
November 26, 2024 7:07 AM UTC(Updated - November 26, 2024 7:11 AM EST)
Amgen (NASDAQ: AMGN) Falls 8% Following Obesity Data, Rivals Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO) Gain 4%
Amgen (NASDAQ: AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, formerly AMG 133), an investigational antibody peptide conjugate subcutaneously administered monthly or less frequently. In people... MoreAmgen (AMGN) Announces Robust Weight Loss With Maritide In People Living With Obesity Or Overweight At 52 Weeks In A Phase 2 Study
November 26, 2024 7:05 AM UTCAmgen (NASDAQ: AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, formerly AMG 133), an investigational antibody peptide conjugate subcutaneously administered monthly or less frequently. In people living with obesity or overweight without Type 2 diabetes, MariTide demonstrated up to ~20% average weight loss at week 52 without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks.1 The study also showed people living with obesity or overweight and Type 2 diabetes, who typically lose less weight... More
